{"id":19351,"date":"2026-06-11T04:59:00","date_gmt":"2026-06-11T02:59:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=90cc1d54e0a9a4e2777a42283d50f964"},"modified":"2026-06-11T04:59:00","modified_gmt":"2026-06-11T02:59:00","slug":"equity-alert-rosen-law-firm-files-securities-class-action-lawsuit-on-behalf-of-adma-biologics-inc-investors-adma","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=19351","title":{"rendered":"EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of ADMA Biologics, Inc. Investors \u2013 ADMA"},"content":{"rendered":"<p style=\"text-align:justify\">NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the \u201cClass Period\u201d). The lawsuit seeks to recover damages for ADMA Biologics investors under the federal securities laws.<\/p><p style=\"text-align:justify\">To join the ADMA Biologics class action, go to <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Frosenlegal.com%2Fcases%2Fadma-biologics-inc%2Fjoin&amp;esheet=54551643&amp;newsitemid=20260610687715&amp;lan=en-US&amp;anchor=https%3A%2F%2Frosenlegal.com%2Fcases%2Fadma-biologics-inc%2Fjoin&amp;index=49&amp;md5=4770f547233a042bec910d10063b0df2\" rel=\"nofollow\" shape=\"rect\">https:\/\/rosenlegal.com\/cases\/adma-biologics-inc\/join<\/a> or call Phillip Kim, Esq. toll-free at 866-767-3653 or email <a  href=\"mailto:case@rosenlegal.com\" rel=\"nofollow\" shape=\"rect\">case@rosenlegal.com<\/a> for information on the class action.<\/p><p style=\"text-align:justify\">According to the lawsuit, defendants throughout the Class Period made false and\/or misleading statements and\/or failed to disclose that: (1) ADMA Biologics engaged in an undisclosed related party transaction; (2) ADMA Biologics used channel stuffing to create an appearance of revenue; (3) ADMA Biologics lacked adequate internal controls; and (4) as a result, defendants\u2019 statements about ADMA Biologics\u2019 business, operations, and prospects were materially false and misleading and\/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.<\/p><p style=\"text-align:justify\">A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court <b>no later than August 10, 2026<\/b>. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Frosenlegal.com%2Fcases%2Fadma-biologics-inc%2Fjoin&amp;esheet=54551643&amp;newsitemid=20260610687715&amp;lan=en-US&amp;anchor=https%3A%2F%2Frosenlegal.com%2Fcases%2Fadma-biologics-inc%2Fjoin&amp;index=50&amp;md5=d4070572f019ebc9f02e311bb21ca18e\" rel=\"nofollow\" shape=\"rect\">https:\/\/rosenlegal.com\/cases\/adma-biologics-inc\/join<\/a> or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at <a  href=\"mailto:case@rosenlegal.com\" rel=\"nofollow\" shape=\"rect\">case@rosenlegal.com<\/a>.<\/p><p style=\"text-align:justify\">NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR\u2019S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.<\/p><p style=\"text-align:justify\">Follow us for updates on LinkedIn: <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm&amp;esheet=54551643&amp;newsitemid=20260610687715&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm&amp;index=51&amp;md5=079842e59faea783cf3482b4f60e8cc5\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.linkedin.com\/company\/the-rosen-law-firm<\/a> or on Twitter: <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Frosen_firm&amp;esheet=54551643&amp;newsitemid=20260610687715&amp;lan=en-US&amp;anchor=https%3A%2F%2Ftwitter.com%2Frosen_firm&amp;index=52&amp;md5=27eb5d0431b5c5624a676223c325c997\" rel=\"nofollow\" shape=\"rect\">https:\/\/twitter.com\/rosen_firm<\/a> or on Facebook: <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm&amp;esheet=54551643&amp;newsitemid=20260610687715&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm&amp;index=53&amp;md5=fca90550d184c95a68ae2189dd2526e9\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.facebook.com\/rosenlawfirm<\/a>.<\/p><p style=\"text-align:justify\">Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm\u2019s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.<\/p><p style=\"text-align:justify\">Attorney Advertising. Prior results do not guarantee a similar outcome.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260610687715\/en\/1164042\/5\/July_30%2C_2021_-_ROSEN_LOGO.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260610687715\/en\/1164042\/22\/July_30%2C_2021_-_ROSEN_LOGO.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260610687715\/en\/1164042\/5\/July_30%2C_2021_-_ROSEN_LOGO.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260610687715\/en\/1164042\/21\/July_30%2C_2021_-_ROSEN_LOGO.jpg\" \/><\/a><br\/> <b>Contacts<\/b> <br\/><p class=\"bwalignl\">Laurence Rosen, Esq.<br\/>Phillip Kim, Esq.<br\/>The Rosen Law Firm, P.A.<br\/>275 Madison Avenue, 40<sup>th<\/sup> Floor<br\/>New York, NY 10016<br\/>Tel: (212) 686-1060<br\/>Toll Free: (866) 767-3653<br\/>Fax: (212) 202-3827<br\/><a  href=\"mailto:case@rosenlegal.com\" rel=\"nofollow\" shape=\"rect\">case@rosenlegal.com<\/a><br\/><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.rosenlegal.com&amp;esheet=54551643&amp;newsitemid=20260610687715&amp;lan=en-US&amp;anchor=www.rosenlegal.com&amp;index=102&amp;md5=712b6fb13fa8ce9c3623fc856c2eeac2\" rel=\"nofollow\" shape=\"rect\">www.rosenlegal.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>NEW YORK&#8211;(BUSINESS WIRE)&#8211;Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-19351","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/19351","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19351"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/19351\/revisions"}],"predecessor-version":[{"id":19352,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/19351\/revisions\/19352"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19351"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19351"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19351"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}